Lannett’s insulin glargine biosimilar candidate will break new ground as it moves through the 351(k) review pathway, according to Ha Kung Wong, an intellectual property law attorney with Venable of New York.
Based on an announcement last week, the longtime generics manufacturer Lannett would become among the first to file for insulin glargine product approval under the 351(k) Biologics License Application pathway.
Lannett’s progress through the 351(k) review process will be interesting to observe, said Ha Kung Wong, an intellectual property law attorney with Venable of New York.
Insulin products have previously tended to be approved under the 505(b)(2) pathway, under which applicants have had to do clinical studies to gain approval. Two phase 3 studies were done for Basalgar, Wong noted. So, it will be interesting to see whether the clinical testing requirements for Lannett’s insulin glargine candidate under 351(k) are as rigorous or less so, he said.
It will also be interesting to see whether or how easily Lannett’s insulin glargine obtains “interchangeable status,” which would mean pharmacists could decide on their own whether to fill prescriptions with this or Lantus. Much depends on the extent FDA’s interchangeability standards actually differ under the 351(k) pathway in practice for follow-on insulin products versus for other biosimilars, Wong said.
“Interchangeability status will give the follow-on insulin automatic substitution, depending on the state, at the pharmacy level, something that follow-on insulin via the 505(b)(2) pathway did not have access to. However, we know that interchangeability status typically requires additional testing,” he said.
He added that pursuant to the FDA’s guidance, if a biosimilar candidate under the 351(k) pathway passes a highly rigorous analytical assessment of biosimilarity to the reference product, an immunogenicity or “switching” study might not be required, assuming all other conditions are met. “Possibly, interchangeable status comes essentially automatically with biosimilar status for some follow-on insulins, which would make the 351(k) potentially more beneficial for those manufacturers,” Wong said, so this will be closely watched, too.
Besides a 505(b)(2) application, the other former route to approval for a follow-on insulin product was an Abbreviated New Drug Application, which unlike the 505(b)(2) pathway, offered the potential for 6 months of marketing exclusivity for the first filer approved as a generic.
The current guidelines on interchangeability indicate that, “depending on a number of factors,” a product approved as an interchangeable biosimilar may have as much as a year’s exclusivity, Wong said.
Also last week, the FDA approved an insulin glargine (Semglee) under the 505(b)(2) pathway. The drug automatically is deemed approved under section 351(a) of the Public Health Service Act of the Biologics Price Competition and Innovation Act. For the full story, click here.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.